Eko Health launches AI-enabled stethoscope. The CORE 300 stethoscope combines traditional and digital listening, with app-based AI analysis for structural heart murmurs. By Eve Bender, Healthcare Reporter | October 22, 2026 | 2:42 PM Eko Health's CORE 300 stethoscope Digital cardiac and lung health company Eko Health has launched its FDA-cleared CORE 300 stethoscope for adult and pediatric patients, combining traditional listening with digital audio and access to AI-assisted murmur detection. Clinicians can twist the chestpiece to switch between traditional listening and three digital modes: Cardiac, Pulmonary and All Purpose. The device offers up to 35 times sound amplification, adjustable volume and active noise cancellation, while a built-in screen displays heart rate in real time. When paired with the Eko App, the stethoscope allows clinicians to record, visualize and save heart, lung and other body sounds. Eko's FDA-cleared AI analyzes recordings for suspected structural heart murmurs to support clinical assessment. The company's website lists the device at $199. Access to AI analysis requires an Eko+ membership, which renews at $119.99 annually following a 14-day trial included with the stethoscope purchase. Eko says the device's battery supports up to 120 hours of clinical use. It also has USB-C charging and a shatter-resistant display, while traditional listening works without battery power. "The goal is to help clinicians recognize signs of heart disease earlier, during an exam patients already receive," Eko CMO Dr. Steven Steinhubl told MobiHealthNews. When a concerning heart murmur is detected with the CORE 300 and Eko's FDA-cleared murmur detection AI, this prompts the need for further evaluation, including an echocardiogram and, when appropriate, referral for treatment or intervention, Steinhubl said. This can be especially valuable in primary care and rural settings, where access to cardiology may be limited, he explained. "The goal with CORE 300 is to put this technology in the hands of many more healthcare professionals, using a familiar and affordable tool that can be part of a routine exam," said Steinhubl. The company announced U.S. availability beginning Oct. 22, with launches planned in Canada, the UK and select European markets, followed by additional countries. The FDA granted the CORE 300 510(k) clearance on July 23. THE LARGER TREND In April 2025, Eko expanded its digital stethoscope platform to the UK market, making its CORE 500 device, Eko+ membership and accessories available directly to clinicians. The device includes three-lead ECG capabilities, digital audio and AI insights. In 2024, the company received FDA clearance for its Eko Low Ejection Fraction Tool, which helps identify low ejection fraction, a key indicator of heart failure, during a routine exam. The tool was developed for Eko's SENSORA Cardiac Early Detection Platform, which also included algorithms for atrial fibrillation and structural heart murmurs. Eve Bender, healthcare reporter for MobiHealthNews Email: [email protected] MobiHealthNews is a HIMSS Media publication. Follow MobiHealthNews on LinkedIn: MobiHealthNews WATCH NOW: Medicare Advantage represents a 'huge chunk' of spending

Eko Health welcomes Dave Gwin as SVP of Health Systems. October 19, 2026 Emeryville, CA - October 19, 2026 Dave Gwin joins Eko Health as Senior Vice President of Health Systems, bringing more than 16 years of experience building and scaling commercial organizations across healthcare technology, medical imaging, and oncology software. Prior to joining Eko, Dave held progressive commercial leadership roles at MIM Software and GE HealthCare, where he helped drive sustained revenue growth, developed high-performing teams, and expanded strategic partnerships with leading health systems. His experience spans bringing innovative clinical technologies to market, executing complex enterprise agreements, and supporting commercial growth through MIM's acquisition by GE HealthCare. At Eko, Dave will lead the Health System Commercial organization, focusing on accelerating growth, strengthening strategic partnerships, and expanding adoption of Eko's AI-powered cardiovascular detection technology. "Dave brings a unique combination of commercial discipline and deep health system relationships that this stage of Eko's growth demands. We're thrilled to welcome him as we expand adoption of our AI-powered cardiovascular detection technology," said Connor Landgraf, co-founder and CEO of Eko Health. Dave's arrival comes on the heels of recent announcements including the publication of the TRICORDER study in The Lancet, CMS's finalization of OPPS payment for the SENSORA(R) platform, and Wayne General Hospital's partnership with Eko to deploy AI-assisted cardiac detection in rural Mississippi. "Throughout my career, I've focused on helping health systems bring innovative technology into clinical practice and improving patient care at scale," said Gwin. "What drew me to Eko was the mission, the people, and the opportunity to help clinicians with early detection of cardiopulmonary disease. I'm excited to build on the team's momentum, strengthen our health system partnerships, and bring these tools to more clinicians and the patients they serve."

TIME: World's Top HealthTech Companies of 2026. September 18, 2026 Eko Health, Inc. is proud to share that TIME has named Eko Health to its 2026 World's Top HealthTech Companies list, earning an "Outstanding" rating in the Medical Devices & Wearables category. The back-to-back recognition marks another milestone in its mission: equipping clinicians with the tools to catch heart and lung disease sooner, with greater precision than ever before.